Polycytemia - Is There a Molecular Response to a Jack Inhibitor?

Ruxolytane was approved as a second line choice after hydroxyurea and here is a study done in uk where they were looking at the benefits beyond controlling those spleen symptoms. By 2024 December we should have some preliminary results I certainly hope so please continue okay moving on to different disease polycytemia era you may recall thatpolycytemia includes uh high rebutsel of course everybody does that then the white cells and platelets but also control the spleen and symptoms.